MS
NGM

Maven Securities’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Maven Securities’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-33,728
Closed -$1.04M – 1331
2020
Q4 		$1.04M Buy
+33,728
New +$738K 0.1% 248

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
GA
Greenspring Associates Owings Mills, Maryland $1.48B AUM 61.93% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return

Maven Securities's NGM Position: Q1 2021 in Review

Maven Securities sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q1 2021, closing a stake of 33,728 shares — an estimated $1.04M sold.

Maven Securities first reported a position in NGM in Q4 2020 and held it in 1 quarter. The position peaked at $1.04M in Q4 2020. 108 funds tracked by Wall St. Rank hold NGM as of Q1 2021.

  • Maven Securities reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Maven Securities sold 33,728 NGM Biopharmaceuticals, Inc. Common Stock shares in Q1 2021, an estimated $1.04M.
  • Maven Securities first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q4 2020 and held it in 1 quarter.
  • Maven Securities's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $1.04M in Q4 2020.
  • 108 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q1 2021.

Based on Maven Securities's 13F filing for Q1 2021, filed 17 May 2021.